Lambda Therapeutic Research is proud to announce the successful completion of a US FDA inspection for pharmacovigilance services, conducted from August 12-16, 2024. Despite receiving short-notice notification just two days prior, Lambda’s dedicated team rose to the challenge, providing seamless support for a client based on the US West Coast—a region with a 12+ hour time zone difference from our headquarters.

This inspection resulted in zero findings, underscoring our unwavering commitment to regulatory excellence and our “Always Inspection Ready” approach. This achievement highlights the effectiveness of our global support framework and our dedication to maintaining the highest standards of compliance and quality.

Lambda Therapeutic Research provides comprehensive drug safety & pharmacovigilance services, encompassing all clinical and post-marketing phases. Our well-established PV framework ensures thorough safety monitoring and regulatory compliance for both clinical and commercial products, offering end-to-end support across the entire life cycle of medicinal products.